세계의 악성 중피종 치료 시장 - 산업 규모, 점유율, 동향, 기회, 예측, 약제 유형별, 투여 경로별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)
Malignant Mesothelioma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By End User, By Region and Competition, 2020-2030F
악성 중피종 치료 세계 시장은 2024년에 2억 4,565만 달러로 평가되었고, 예측 기간 동안 CAGR은 6.54%를 나타낼 전망이며, 2030년에는 3억 6,011만 달러에 이를 것으로 예측됩니다.
악성 중피종은 흉부, 복부, 심장을 덮는 중피 세포를 침범하는 희귀하고 공격적인 형태의 암입니다. 이 질환은 주로 석면 노출과 관련이 있으며, 그 예후는 종종 나쁩니다. 그러나 최근 종양학과 제약 업계의 진보로 악성 중피종 치료 시장이 확대되고 있습니다. 악성 중피종은 상대적으로 드문 질병이지만, 그 발생률은 세계적으로 증가하고 있습니다. 이것은 진단 지연 및 석면 노출과 관련된 긴 잠복기 기간으로 인해 발생합니다. 바이오마커 식별 및 영상 진단 기술과 같은 진단 기술의 향상으로 중피종의 조기 발견이 가능해졌습니다. 조기 진단은 효과적인 치료에 필수적입니다. 제약 산업에서는 악성 중피종에 대한 새로운 치료법과 치료 접근법이 개발되었습니다. 이러한 치료법에는 면역요법, 표적요법, 유전자요법 등이 있어 보다 좋은 치료결과가 기대되고 있습니다. 많은 국가의 정부는 석면의 사용을 제한하는 규제를 도입하고 있으며, 미래에 중피종의 발생을 줄일 수 있습니다. 또한, 건강 관리 개혁은 이환자의 치료에 대한 접근성을 향상시키는 것을 목표로 합니다. 세계의 악성 중피종 치료 시장은 진단과 치료 옵션의 발전으로 큰 성장을 이루고 있습니다. 이 공격적인 암으로 진단받은 환자는 혁신적인 치료법과 연구의 진전에 의해 그 어느 때보다 희망을 갖게 되었습니다. 도전 과제는 여전히 존재하지만, 제약회사, 연구기관, 지원단체의 헌신적인 노력으로 악성 중피종을 앓고 있는 환자에게 밝은 미래가 약속되고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
2억 4,565만 달러 |
| 시장 규모 : 2030년 |
3억 6,011만 달러 |
| CAGR : 2025-2030년 |
6.54% |
| 급성장 부문 |
페메트렉시드 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
악성 중피종 발생률 증가
주요 시장 과제
제한된 인지도와 조기 진단
주요 시장 동향
면역요법 및 표적요법에 대한 관심 증가
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 악성 중피종 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 약제 유형별(페메트렉세드, 시스플라틴, 카르보플라틴, 젬시타빈, 비노렐빈, 기타)
- 투여 경로별(경구, 비경구)
- 최종 사용자별(병원, 암 센터, 기타)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 악성 중피종 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 악성 중피종 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 악성 중피종 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 악성 중피종 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 악성 중피종 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
- 합병과 인수(있는 경우)
- 제품 발매(있는 경우)
- 최근 동향
제13장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체품의 위협
제14장 경쟁 구도
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Merck & Co. Inc.
- Pfizer Inc.
- Eli Lilly and Co.
- Sanofi SA
- AstraZeneca Plc
- Bayer AG
- Regeneron Pharmaceuticals Inc.
- GSK Plc
제15장 전략적 제안
제16장 기업 소개와 면책사항
SHW
Global Malignant Mesothelioma Therapeutics Market was valued at USD 245.65 Million in 2024 and is expected to reach USD 360.11 Million by 2030 with a CAGR of 6.54% during the forecast period. Malignant mesothelioma is a rare and aggressive form of cancer that affects the mesothelial cells lining the chest, abdomen, and heart. This disease is primarily associated with asbestos exposure, and its prognosis is often bleak. However, recent advancements in the field of oncology and the pharmaceutical industry have given rise to a growing market for malignant mesothelioma therapeutics. While malignant mesothelioma remains relatively rare, its incidence has been increasing globally. This is partly due to delayed diagnoses and the long latency period associated with asbestos exposure. Improved diagnostic techniques, including biomarker identification and imaging technologies, have enabled earlier detection of mesothelioma. Early diagnosis is critical for effective treatment. The pharmaceutical industry has witnessed the development of novel therapies and treatment approaches for malignant mesothelioma. These include immunotherapy, targeted therapy, and gene therapy, which offer hope for better outcomes. Governments in many countries have introduced regulations to restrict asbestos use, which can potentially reduce future cases of mesothelioma. Additionally, healthcare reforms aim to improve access to treatment for affected individuals. The global malignant mesothelioma therapeutics market is witnessing significant growth, driven by advancements in diagnosis and treatment options. Patients diagnosed with this aggressive cancer now have more hope than ever before, thanks to innovative therapies and a growing body of research. While challenges still exist, the dedication of pharmaceutical companies, research institutions, and advocacy groups promises a brighter future for those affected by malignant mesothelioma.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 245.65 Million |
| Market Size 2030 | USD 360.11 Million |
| CAGR 2025-2030 | 6.54% |
| Fastest Growing Segment | Pemetrexed |
| Largest Market | North America |
Key Market Drivers
Increasing Incidence Rates of Malignant Mesothelioma
Malignant mesothelioma, a rare and aggressive cancer primarily associated with asbestos exposure, has been on the rise globally in recent years. This alarming increase in incidence rates has spurred significant research and development efforts in the field of mesothelioma therapeutics. As more individuals are diagnosed with this devastating disease, the demand for effective treatment options is growing, driving the global malignant mesothelioma therapeutics market forward. According to
Key Market Challenges
Limited Awareness and Early Diagnosis
One of the most significant hurdles in managing malignant mesothelioma is the widespread lack of awareness about the disease, both among the general public and healthcare professionals. Mesothelioma is a rare and aggressive form of cancer, often linked to asbestos exposure, but its symptoms are vague and non-specific, such as chest pain, shortness of breath, and fatigue. These overlapping symptoms are commonly associated with other, more prevalent conditions, which can cause delays in diagnosis. Unfortunately, this leads to diagnoses at later, more advanced stages of the disease, making effective treatment much more difficult. Early detection is key to improving prognosis, but without routine screening methods, identifying mesothelioma at an earlier stage remains a challenge. In addition, because healthcare providers may not regularly suspect mesothelioma in patients with such symptoms, the disease is often misdiagnosed or overlooked until it is too late. Public awareness campaigns, as well as ongoing education for healthcare professionals, are crucial to improving early detection rates and providing patients with better treatment outcomes.
Key Market Trends
Increasing Focus on Immunotherapies and Targeted Therapies
The increasing focus on immunotherapies and targeted therapies is rapidly transforming the Global Malignant Mesothelioma Therapeutics Market. Traditional treatments for mesothelioma, including chemotherapy and radiation, have proven limited in their effectiveness due to the aggressive nature of the disease and its resistance to conventional treatment approaches. In recent years, however, there has been a paradigm shift toward developing more advanced, targeted therapies and immunotherapies that leverage the body's immune system to fight cancer more effectively. In March 2023, Merck, in collaboration with the Canadian Cancer Trials Group (CCTG), has reported that their Phase 2/3 trial, known as CCTG IND.227/KEYNOTE-483, assessing the effectiveness of KEYTRUDA, Merck's anti-PD-1 therapy, combined with chemotherapy, has successfully achieved its primary goal of improving overall survival (OS) in the initial treatment of individuals diagnosed with unresectable advanced or metastatic malignant pleural mesothelioma.
Immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, are showing great promise in mesothelioma treatment. These therapies work by enhancing the body's immune response to tumor cells or by directly targeting the cancerous cells themselves. The success of immunotherapies in other cancers, such as melanoma and non-small cell lung cancer, has sparked increased interest in their application for mesothelioma. Research into the use of immune checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), in combination with traditional treatments has shown encouraging results, leading to clinical trials and ongoing investigations into their potential.
Key Market Players
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Merck & Co. Inc.
- Pfizer Inc.
- Eli Lilly and Co.
- Sanofi S.A.
- AstraZeneca Plc
- Bayer AG
- Regeneron Pharmaceuticals Inc.
- GSK Plc
Report Scope:
In this report, the Global Malignant Mesothelioma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Malignant Mesothelioma Therapeutics Market, By Drug Type:
- Pemetrexed
- Cisplatin
- Carboplatin
- Gemcitabine
- Vinorelbine
- Others
Malignant Mesothelioma Therapeutics Market, By Route of Administration:
Malignant Mesothelioma Therapeutics Market, By End User:
- Hospitals
- Cancer Centers
- Others
Malignant Mesothelioma Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Malignant Mesothelioma Therapeutics Market.
Available Customizations:
Global Malignant Mesothelioma Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Malignant Mesothelioma Therapeutics Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others)
- 5.2.2. By Route of Administration (Oral, Parenteral)
- 5.2.3. By End User (Hospitals, Cancer Centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. North America Malignant Mesothelioma Therapeutics Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Route of Administration
- 6.2.3. By End User
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Malignant Mesothelioma Therapeutics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug Type
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By End User
- 6.3.2. Canada Malignant Mesothelioma Therapeutics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug Type
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By End User
- 6.3.3. Mexico Malignant Mesothelioma Therapeutics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug Type
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By End User
7. Europe Malignant Mesothelioma Therapeutics Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Route of Administration
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Type
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By End User
- 7.3.2. United Kingdom Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Type
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By End User
- 7.3.3. Italy Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Type
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By End User
- 7.3.4. France Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug Type
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By End User
- 7.3.5. Spain Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug Type
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By End User
8. Asia-Pacific Malignant Mesothelioma Therapeutics Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Route of Administration
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Type
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By End User
- 8.3.2. India Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Type
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By End User
- 8.3.3. Japan Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Type
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By End User
- 8.3.4. South Korea Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Type
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By End User
- 8.3.5. Australia Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Type
- 8.3.5.2.2. By Route of Administration
- 8.3.5.2.3. By End User
9. South America Malignant Mesothelioma Therapeutics Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Route of Administration
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Malignant Mesothelioma Therapeutics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Type
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By End User
- 9.3.2. Argentina Malignant Mesothelioma Therapeutics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Type
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By End User
- 9.3.3. Colombia Malignant Mesothelioma Therapeutics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Type
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By End User
10. Middle East and Africa Malignant Mesothelioma Therapeutics Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Route of Administration
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Malignant Mesothelioma Therapeutics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Type
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Malignant Mesothelioma Therapeutics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Type
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By End User
- 10.3.3. UAE Malignant Mesothelioma Therapeutics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Type
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porter's Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. F. Hoffmann-La Roche Ltd
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Novartis AG
- 14.3. Merck & Co. Inc.
- 14.4. Pfizer Inc.
- 14.5. Eli Lilly and Co.
- 14.6. Sanofi S.A.
- 14.7. AstraZeneca Plc
- 14.8. Bayer AG
- 14.9. Regeneron Pharmaceuticals Inc.
- 14.10. GSK Plc
15. Strategic Recommendations
16. About Us & Disclaimer
